Insulin: Side Effects

Safety Notice#

The safety profile of Insulin in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

Objective and plan status: We searched clinical trials, labels, pharmacovigilance, and preclinical summaries for insulin adverse effects with quantitative frequency and severity, and compiled a structured artifact. Animal data were extracted from label monographs with dosing and severity context.

Key findings are summarized below and in the embedded table.

Overall adverse effects in humans with frequency and severity

• Hypoglycemia: In a 24-week open-label ENTUZITY (human regular insulin U-500) study in adults with type 2 diabetes (n=323), documented symptomatic hypoglycemia occurred in 91.0% (294/323) of patients; severe hypoglycemia occurred in 3/162 (1.9%) on TID dosing and 6/161 (3.7%) on BID dosing. Overall hypoglycemia event rates were 41.50 (TID) and 51.55 (BID) events per patient-year; nocturnal hypoglycemia rates were 11.08 (TID) and 14.40 (BID) events per patient-year, with 79.3% (256/323) experiencing nocturnal events (agentUnknownyearentuzity™kwikpen® pages 13-16, agentUnknownyearentuzity™kwikpen® pages 11-13).
• Weight gain: ENTUZITY study reported mean weight gain ≈5.4 kg (TID) and ≈4.9 kg (BID) over 24 weeks; labels recognize weight gain as expected with insulin’s anabolic effects.
• Peripheral edema/“insulin edema”: ENTUZITY reported peripheral edema in 4.3% (TID) and 6.2% (BID) and “oedema” in ~2.5–3.1%; labels note sodium retention and edema can occur, particularly after intensification.
• Injection-site reactions: Pooled phase 3 SOLIQUA (insulin glargine/lixisenatide) studies reported injection-site reactions in 1.7%. Labels list typical local reactions (pain, erythema, nodules); FAERS for insulin glargine shows signals for injection-site pain (3,613 reports) and hemorrhage (1,271) but does not provide incidence.
• Lipodystrophy (lipohypertrophy/lipoatrophy): Listed in labels; FAERS for glargine confirms acquired lipodystrophy as a reported signal. Rates vary by cohort and are not quantified in these excerpts.
• Hypersensitivity and anaphylaxis: BASAGLAR trials reported treatment-emergent allergic events 7.5% with BASAGLAR vs 4.1% with Lantus in one study; labels warn that severe generalized allergy including anaphylaxis can occur, though incidence is not quantified in the excerpts (agent2017basaglar™ pages 8-11, agentUnknownyearentuzity™kwikpen® pages 13-16).
• Hypokalemia: Listed as a labeled warning with insulin-containing products.
• Immunogenicity/antibodies: Anti–insulin glargine antibodies developed in ~21–26% by ~30 weeks in pooled studies; ENTUZITY data suggest minimal immunogenicity to the E. coli polypeptide carrier; clinical significance is generally limited in the provided sources.
• Pharmacovigilance severity signals: FAERS for insulin glargine identified 97,350 reports, confirming known ADEs (hypoglycemia, injection-site issues, acquired lipodystrophy) and flagged unexpected signals (e.g., pancreatic neoplasm, medullary thyroid cancer); among reports, deaths were 3.10% and hospitalizations 13.00%, but these are counts without denominators and cannot be interpreted as incidence.
• Reproductive toxicity/pregnancy: BASAGLAR label notes animal data do not indicate reproductive toxicity and >1000 post-marketing pregnancy outcomes for Lantus showed no specific maternal/fetal adverse effects in these summaries (agent2017basaglar™ pages 8-11).

Animal/preclinical adverse effects

• Acute and repeat-dose toxicity: ENTUZITY monograph reports minimal lethal subcutaneous dose >10 U/kg in rats/mice. Dogs displayed marked hypoglycemia at 2 U/kg SC or 0.1 U/kg IV. One‑month repeat dosing in rats (2.4 U/kg/day SC) and dogs (2 U/kg SC or 0.1 U/kg IV daily) caused pharmacologic hypoglycemia without adverse hematology/chemistry or pathologic changes; no tissue damage at injection sites (agentUnknownyearentuzity™kwikpen® pages 24-27).
• Genotoxicity and carcinogenicity: ENTUZITY genotoxicity testing was negative in Ames, rat hepatocytes, and CHO assays; carcinogenicity studies were not detailed in the provided excerpts. FAERS signals are hypothesis-generating and do not establish causality.
• Reproductive studies: BASAGLAR label indicates animal data without reproductive toxicity; ENTUZITY excerpt notes fertility studies not performed (agent2017basaglar™ pages 8-11, agentUnknownyearentuzity™kwikpen® pages 11-13).

Interpretation and caveats

• Rates per patient-year and frequencies are product- and regimen-specific. ENTUZITY U-500 data reflect high-dose concentrated human regular insulin in insulin‑resistant type 2 diabetes and may not generalize to other insulins or populations. FAERS disproportionality signals reflect reporting, not incidence or causality. Label warnings (hypoglycemia, hypokalemia, edema, hypersensitivity) apply across insulin products; exact frequencies vary by study and are incompletely quantified in the excerpts available.

Contraindications#

Contraindications

• Hypersensitivity to insulin or any component of the formulation; serious systemic allergy can occur and may require discontinuation.
• Active hypoglycemia: do not administer insulin during an episode; treat the low glucose first.
• Inhaled insulin: chronic lung disease (asthma, COPD) due to risk of acute bronchospasm and pulmonary function decline; inhaled insulin is contraindicated in these patients.

Key cautions and label warnings

• Hypoglycemia: the most frequent adverse reaction; risk rises with intensive control and with combination therapy.
• Hypokalemia: all insulins shift potassium intracellularly; monitor potassium in at-risk patients (e.g., on potassium‑lowering drugs or with conditions causing K+ loss).
• Fluid retention/heart failure with thiazolidinediones (TZDs) when used with insulin; use caution or avoid in heart failure.

Drug and substance interactions Increase risk of hypoglycemia (additive glucose lowering or impaired counterregulation)

• Other antidiabetics: sulfonylureas, meglitinides, DPP‑4 inhibitors, GLP‑1 receptor agonists, and pramlintide can increase hypoglycemia risk when combined with insulin; dose reduction of secretagogues is often needed and close glucose monitoring is recommended.
• MAO inhibitors; salicylates; H2‑receptor antagonists; tricyclic antidepressants; sulfonamides/trimethoprim: reported to potentiate hypoglycemia with insulin or sulfonylureas; monitor closely and consider dose adjustments.
• Quinolone antibiotics: case reports describe severe hypoglycemia with antidiabetics; use caution and monitor.
• Ethanol (alcohol): inhibits gluconeogenesis, prolonging and worsening insulin‑associated hypoglycemia, and can blunt counterregulation; advise intake with food and vigilant monitoring or avoidance when fasting.
• Pentamidine (inhaled/systemic): associated with profound hypoglycemia; monitor frequently.
• Beta‑blockers: increase hypoglycemia risk in some settings and mask adrenergic warning symptoms; prefer cardioselective agents if needed and intensify monitoring.

Reduce insulin effect / worsen glycemic control (counter‑regulatory or insulin‑resistance effects)

• Glucocorticoids: increase hepatic glucose production and insulin resistance; anticipate higher insulin requirements and frequent monitoring.
• Thiazide and loop diuretics: impair glucose tolerance and cause potassium loss; monitor glucose and potassium and adjust insulin.
• Sympathomimetics: raise glucose via adrenergic stimulation of glycogenolysis/gluconeogenesis; may reduce apparent insulin effect; monitor and adjust.
• Antipsychotics (typical and atypical): associated with insulin resistance and impaired secretion; monitor and adjust therapy.
• Niacin (nicotinic acid): can worsen insulin resistance and increase glucose/HbA1c; monitor and adjust.
• Estrogens/oral contraceptives: can alter carbohydrate metabolism; monitor and adjust.
• Calcineurin inhibitors/protease inhibitors: associated with post‑transplant or treatment‑related hyperglycemia; insulin often required; monitor and titrate.

Potassium-related interactions (additive hypokalemia)

• Insulin lowers serum potassium; concomitant potassium‑wasting diuretics, beta‑agonists, or amphotericin B increase risk of hypokalemia and arrhythmias; monitor serum potassium and ECG if severe, and replace potassium as needed.

Mechanism-based/theoretical interactions

• Agents increasing counter‑regulatory hormones or adrenergic tone (e.g., sympathomimetics) can oppose insulin’s effect and raise glucose.
• Agents that enhance insulin sensitivity or depress hepatic glucose output (e.g., ethanol during fasting) can precipitate or prolong hypoglycemia when combined with insulin.
• Drugs that lower potassium (beta‑agonists, thiazide/loop diuretics, amphotericin B) have additive hypokalemia with insulin’s intracellular K+ shift.
• Beta‑blockers mask adrenergic warning signs of hypoglycemia (tachycardia, tremor), increasing risk of unrecognized severe hypoglycemia; prefer cardioselective agents when possible and intensify monitoring.

Administration and practical considerations

• Switching among insulin products should be done under medical supervision to avoid dosing errors and severe dysglycemia; monitor glucose closely during transitions.
• For inhaled insulin, avoid use in patients with asthma/COPD and monitor pulmonary function as indicated.

Reference table

Toxicology#

We synthesized toxicological information on insulin by surveying preclinical and clinical evidence for acute lethality, organ/system toxicity, mutagenicity, carcinogenicity, and dose–response features. Where the evidence base was incomplete in the retrieved texts (e.g., LD50 and standard genotoxicity assays), we indicate the gaps explicitly.

Key findings at a glance

Acute lethality (LD50). No quantitative LD50 values for insulin were identified in the retrieved sources. Reviews centered on mechanistic mitogenicity and longer-term tumor endpoints rather than acute lethality metrics; consequently, LD50 data were not reported in the available excerpts.

Organ and systemic toxicity. In rodent studies, the principal toxic effect of insulin and analogues is pharmacologic hypoglycemia, with weight gain as a common secondary effect at higher chronic exposures; such effects complicate interpretation of long-term toxicology studies. Reported organ-level findings include modest mammary gland proliferation in juvenile animals treated with insulin detemir in some studies, whereas broader systemic histopathology signals (e.g., lymphadenopathy, spontaneous solid tumors) were not consistently observed. In insulin‑resistant rats given suprapharmacologic daily dosing (20–150 IU/kg/day), colonic epithelial proliferation and aberrant crypt foci increased irrespective of insulin type; glargine did not exceed NPH for these endpoints.

Mutagenicity/genotoxicity. The retrieved texts did not report outcomes of standard mutagenicity batteries (Ames, chromosome aberration, micronucleus) for human insulin or marketed analogues. Contemporary reviews emphasize that concerns for cancer relate predominantly to mitogenic signaling (promotion) rather than direct mutagenicity; no assay results were provided in the excerpts examined.

Carcinogenicity. A lifetime (2‑year) rat study with insulin glargine reported no tumor‑promoting activity greater than human insulin; exposure during the study encompassed parent compound and active metabolites, with plasma concentrations in the 15–25 nmol/L range. By contrast, the B10‑substituted analogue AspB10 increased mammary adenocarcinomas and fibroepithelial tumors in female Sprague–Dawley rats and displayed higher affinity for the insulin and IGF‑1 receptors with slower receptor off‑rate, consistent with sustained signaling. Clinical epidemiology aligns with a lack of carcinogenic signal at therapeutic exposure: the large ORIGIN trial found hazard ratios near 1.0 for overall cancer and cancer mortality, and meta‑analytic syntheses are broadly consistent with no increased overall cancer risk for currently marketed analogues at clinical doses.

Dose–response relationships. In vivo signaling studies in rats show that single subcutaneous doses of 1–200 U/kg of human insulin or glargine do not produce detectable IGF‑1 receptor autophosphorylation in muscle or heart, whereas AspB10 elicits higher and prolonged insulin receptor/Akt phosphorylation, indicating a distinct signaling intensity/time profile. Chronic daily dosing at 20–150 IU/kg/day increased colonic epithelial proliferation in insulin‑resistant rats irrespective of insulin type. In vitro, glargine can provoke increased IGF1R‑related mitogenic signaling in certain cell lines at supraphysiologic concentrations (typically ~1–100+ nM), while its major metabolites M1 and M2 exhibit mitogenic potency comparable to human insulin. Therapeutic free serum glargine concentrations in humans are on the order of 70–200 pmol/L—orders of magnitude lower than IGF‑1 levels and far below the concentrations driving in vitro mitogenesis; severe hypoglycemia limits the ability to achieve higher systemic exposures clinically.

Conclusions. The dominant toxicological hazard of insulin across species is hypoglycemia, with downstream effects of weight gain and, at very high doses in susceptible models, proliferative changes in select tissues. Carcinogenicity concerns are analogue‑specific: AspB10 is tumorigenic in rats, while marketed analogues such as glargine have not shown greater tumor‑promoting activity than human insulin in lifetime rodent studies and do not exhibit a consistent carcinogenic signal epidemiologically. The retrieved corpus did not report LD50 values or results from standard mutagenicity assays for insulin; extant reviews focus on mitogenic promotion rather than genotoxic initiation.

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• Insulin overview and research guide
• Insulin dosing protocols
• Insulin risks and legal status